Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling
Roslin Institute · University of Edinburgh · +15 more institutions
Abstract
CTNNB1, the gene encoding β-catenin, is a frequent target for oncogenic mutations activating the canonical Wnt signaling pathway, typically through missense mutations within a degron hotspot motif in exon 3. Here, we combine saturation genome editing with a fluorescent reporter assay to quantify signaling phenotypes for all 342 possible missense mutations in the mutation hotspot. Our data define the genetic requirements for β-catenin degron function, refine the consensus motif for substrate recognition by β-TRCP and reveal diverse levels of signal activation among known driver mutations. Tumorigenesis in different human tissues involves selection for CTNNB1 mutations spanning distinct ranges of predicted…
Citation impact
- FWCI
- 47.03
- Percentile
- 100%
- References
- 60
Authors
27- AKAnagha KrishnaCorresponding
Roslin Institute, University of Edinburgh
- AMAlison Meynert
Institute of Genetics and Cancer, University of Edinburgh
- KSKaramjit Singh Dolt
Leiden University
- MKMartijn Kelder
Institute of Genetics and Cancer, University of Edinburgh
- AMAgavni Mesropian
Departament de Salut, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona
Topics & keywords
- Missense mutation
- Gene
- Carcinogenesis
- Phenotype
- Exon
- Mutation
- Wnt signaling pathway
- Mutant
Funding
- WTWellcome TrustAward: 102560
- CRCancer Research UKAward: A26813
- ECEuropean CommissionAward: 101136622
- FCFundación Científica Asociación Española Contra el CáncerAwards: R01DK128289, EPAEC246711CLIN, RETOS245779LLOV, R01DK56621, PRYGN223117LLOV, LCF/PR/SP23/52950009
- GDGeneralitat de CatalunyaAward: 2021 FISDU 00338
- MDMinisterio de Ciencia e InnovaciónAwards: 13039, AEI/10, PID2022-139365OB-I00, /AEI/10, PID2022
- AIAssociazione Italiana per la Ricerca sul CancroAward: A26813
- UDUniversitat de Barcelona
- NINational Institutes of HealthAwards: BB/P013732/1, P30CA008748, R01DK56621, R01DK128289, R01HD035455, R01-CA273932-01
- HEHORIZON EUROPE Framework ProgrammeAwards: 101136622, Ref. 101136622
- MRMedical Research CouncilAwards: MR/M010341/1, BB/P013732/1, MC_UU_00035/1
- BABiotechnology and Biological Sciences Research CouncilAward: BB/P013732/1
- ADAgència de Gestió d'Ajuts Universitaris i de RecercaAward: LCF/PR/SP23/52950009
- AEAgencia Estatal de InvestigaciónAwards: 13039, AEI/10